Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for review of tofersen, an investigational drug for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). SOD1-ALS is a progressive and uniformly fatal disease that affects less than 1,000 people in Europe.2 There is currently no treatment targeted for SOD1-ALS.3

European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS

Regeneron Pharmaceuticals

Both are riding the wave of major clinical wins

Can These 2 Stocks Crush the Market Again in 2023?

Biogen Inc. (NASDAQ:BIIB ) 5th Annual Evercore ISI HealthCONx Conference Call December 1, 2022 10:30 AM ET Company Participants Mike McDonnell - Chief Financial Officer Priya Singhal - Head of Global Safety and Regulatory Sciences and Interim Head of R&D Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Hello, everyone. Pleasure to have Biogen management join us right after Merck and there's a lot to talk about, but let me turn it over to you, Mike, to kick things off.

Biogen Inc. (BIIB) 5th Annual Evercore ISI HealthCONx Conference 2022 - (Transcript)

Japan's Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year.

Eisai, Biogen Alzheimer's drug could be available to some next year

Shares of Eisai and Biogen did not move dramatically after the drug companies reported the full results of the clinical trial for their experimental Alzheimer's disease therapy, but the findings point to a stable future for lecanemab once it is approved by the U.S. Food and Drug Administration.

5 things to know about the new Alzheimer's drug — including why it may be risky for people who take blood thinners

Detailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of cognitive decline but is associated with adverse events like brain hemorrhage.

Biogen's (BIIB) Lecanemab Shows Benefit but With Side Effects

Biogen (NASDAQ: BIIB ) stock is on the move Wednesday after the company provided the latest update on its Alzheimer's drug candidate. According to a press release from the biotechnology company, lecanemab performed well in a Phase 3 clinical trial.

BIIB Stock Alert: What the Latest Alzheimer's Drug Data Means for Biogen

Biogen Inc (NASDAQ: BIIB) shares are trading higher Wednesday after the company announced positive trial results for its experimental Alzheimer's

Biogen Stock Is Surging Today: What's Going On? - Biogen (NASDAQ:BIIB)

Studies show that lecanemab can clear the damage causing protein amyloid from the brain, slowing the progress of the disease.

New drug brings hope that decades-long slog to find Alzheimer's cure might pay off

ABIOMED

Albemarle

Constellation Energy Corp

Dollar General

DexCom

Enphase Energy

Halliburton

SolarEdge Technologies

Wynn Resorts

Most S&P 500 investors got a little gain this month. But investors willing to look off the beaten path found huge gains.

Eleven Stocks Turned $10,000 To $261,421 In 11 Months

Biogen Inc. stock BIIB, -0.17% rose 3% in premarket trade Wednesday, after a new study was unveiled late Tuesday that showed the company's experimental Alzheimer's drug being developed with Japan's Eisai 4523, +3.83% ESALY, -0.54% moderately reduced cognitive decline after a year and a half. The study assessing lecanemab as a treatment for people with early forms of Alzheimer's disease was published Tuesday night by the New England Journal of Medicine.

Biogen stock up 3% premarket after update on Alzheimer's treatment; Stifel reiterates buy rating

Shares in the pharmaceutical companies rose after the publication of a paper detailing the apparent benefits of lecanemab.

Biogen and Eisai Strengthen Lead in Alzheimer's Drug Race. The Stocks Are Rising.

Biogen stock was muted late Tuesday after Eisai unveiled Alzheimer's treatment results likely to spark a debate over the drug's benefits. The post Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors appeared first on Investor's Business Daily.

Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors

Doctors have hailed a "new era" of medicine after a study showed for the first time that a drug can slow the debilitating symptoms of Alzheimer's.

New Alzheimer's drug slows decline in memory - fuelling hope doctors will one day cure dementia

Eisai, Biogen Alzheimer's drug slows cognitive decline, safety for some becomes focus

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, were published in the New England Journal of Medicine, one of the world's most prestigious peer-reviewed medical journals. For the details of the paper, please refer to here.

ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINE

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, were presented at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) conference, in San Francisco, California and virtually.

EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE

Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.

Biogen (BIIB) Down on Report of Death in Alzheimer's Study

Biogen Inc (NASDAQ:BIIB) is under pressure this morning, in the wake of a research paper published on Science.org this Sunday.

Research Paper Reports Death in Biogen's Experimental Drug

Biogen stock toppled Monday after a report suggested its experimental Alzheimer's treatment caused a patient's fatal brain hemorrhage. The post Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success appeared first on Investor's Business Daily.

Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success

Vertex Pharmaceuticals

This pair of stocks are bucking the trend and they could climb even higher.

2 Stocks Near 52-Week Highs That Could Climb Higher

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?

Why Is Biogen Inc. (BIIB) Up 8.2% Since Last Earnings Report?

Repligen

BIIB vs. RGEN: Which Stock Is the Better Value Option?

BIIB or RGEN: Which Is the Better Value Stock Right Now?

SAGE Therapeutics

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the companies will host a joint investor webcast to discuss the planned commercialization approach and opportunity for their investigational product, zuranolone, on Tuesday, December 6 at 8:00 a.m. ET.

Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

News for Biogen Stock (BIIB)